Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 92 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase II-III HMM vs FAC (5-FU/ADR/CTX) Chemotherapy for Advanced Transitional Cell Bladder Cancer with Impaired Renal Function

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				SWOG-7904


2.		Consolidation Hemi-Body Irradiation plus Chemotherapy with CMFP (CTX/MTX/5-FU/PRED) or CAF (CTX/ADR/5-FU) for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				70 and under				NCI				EST-PE-179

Last Modified: 8/10/2007


3.		Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				16 to physiologic 70				NCI				CLB-8642 CALGB-8642


4.		Phase II/III Randomized Comparison of CAF (CTX/ADR/5-FU) vs Palliative Radiotherapy Alone in Patients with Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				over 18								MRH-860408 NCI-V86-0099

Last Modified: 1/1/1998


5.		Phase II Study of Multimodality Therapy for Women with Locally Advanced Breast Cancer: Neoadjuvant Cyclophosphamide/Doxorubicin/Fluorouracil (CAF) Followed by Radiotherapy with Mitomycin Followed by Surgery Followed by Adjuvant CAF or Mitoxantrone/Fluorouracil/Leucovorin (Summary Last Modified 01/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				20 to 65				Other				YALE-HIC-7996 NCI-V95-0728

Last Modified: 12/28/2006


6.		Phase III Randomized Study of Neoadjuvant Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) in Women With Stage III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				21 to 75				Other				GOCS-08-BR-95-III NCI-F95-0036, NCT00002696

Last Modified: 3/1/2000


7.		Phase IIIB Randomized Study of Doxorubicin plus the Cardioprotectant Dexrazoxane vs Observation in Women with Advanced Breast Cancer That is Stable or Responding After 6 Courses of First-Line Cyclophosphamide/Doxorubicin/Fluorouracil (CAF) (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				PHARMACIA-088050 NCI-V96-0828

Last Modified: 9/1/1997


8.		Phase III Randomized Study of High Dose Chemotherapy,Autologous Bone Marrow Transplantation, and Peripheral Blood Stem Cell Autographs, for Patients with High Risk Primary Breast Cancer (Summary Last Modified 09/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Under 65				NCI				MDA-DM-89102 NCI-G96-1012


9.		Phase III Study of Major Hormonal Ablation with or without CAF Chemotherapy for ER Positive Metastatic Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 70								SEG-78BRE0103 SEG-78BRE336


10.		Phase III Medical Adrenalectomy with Aminoglutethimide and HC with or without CAF (CTX/ADR/5-FU) for ER-Positive Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				70 and under								SEG-80BRE370

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute